Mypreto 200 mg Tablets
PDF Leaflet Revision Date: 30 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of pulmonary XDR or treatment-intolerant MDR tuberculosis.
Dosage (summary)
200 mg once daily for 26 weeks, in combination with bedaquiline and linezolid.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential reproductive toxicities.
Key Drug Interactions
- CYP3A4 inducers (e.g., rifampicin, efavirenz)
Contraindications
- Hypersensitivity to pretomanid
- Use with contraindicated medications
Common side effects
- Anaemia
- Peripheral neuropathy
- Visual impairment
- Nausea
- Fatigue
Counselling Points
- Take with food.
- Adhere to the full course of therapy.
- Report any vision changes immediately.
- Avoid alcohol and hepatotoxic medications.
Serious warnings
- Hepatotoxicity
- Myelosuppression
- QT prolongation
- Lactic acidosis
Important Disclaimer
The Mypreto 200 mg Tablets professional information leaflet below is the property of Mylan and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
